RenovoRx (RNXT) Q2 2026 earnings review
Accelerating Commercial Validation, but a Ticking Cash Clock
RenovoRx is proving its commercial model works. Q2 revenue hit a record $909K, accelerating 61% sequentially and 115% YoY, driven purely by the organic adoption of its FDA-cleared RenovoCath device. The company successfully expanded its active commercial cancer center base to 21. Management confidently raised FY26 revenue guidance to $3.75M-$4.25M. However, the balance sheet tells a tense story. With $9.5M in cash remaining and a quarterly net loss of $2.9M, management's goal of reaching cash-flow breakeven by Q4 2027 is mathematically contradictory without an explosive near-term revenue ramp or a significant drop in operating expenses.
🐂 Bull Case
Consecutive record quarters ($563K in Q1 to $909K in Q2) demonstrate accelerating physician adoption. The business is generating 84% gross margins, meaning incremental revenue falls directly to the bottom line.
With the Phase III TIGeR-PaC trial fully enrolled, up to 15 trial sites will transition to commercial utilization in H2 2026, providing a highly predictable, near-term revenue catalyst.
🐻 Bear Case
Management claims $9.5M is sufficient to reach H2 2027. Yet the company burned over $2.9M this quarter alone. Without a severe cut to SG&A or immediate, exponential revenue growth, dilution is highly likely within 12 months.
Selling, General, and Administrative expenses spiked to $2.9M in Q2 (up from $1.5M YoY). The cost of building a commercial footprint is currently outpacing gross profit generation ($766K).
⚖️ Verdict: ⚪
Neutral. The commercial execution is phenomenal and the underlying technology is gaining undeniable traction. However, the glaring discrepancy between current cash burn rates and the projected Q4 2027 breakeven timeline caps the near-term upside due to severe dilution risks.
Key Themes
Active Cancer Center Expansion
Accelerating. The core KPI of this business—active commercial cancer center customers—grew from 16 in Q1 to 21 in Q2 (a 30% sequential jump). Furthermore, the total commercial pipeline expanded to 63 centers. Management expects to exceed its target of 36 active centers by year-end, solidifying a scalable, recurring revenue base for its single-use device.
Clinical Trial Sites Converting to Commercial Customers
Accelerating. The Phase III TIGeR-PaC trial reached full enrollment in August 2026. As a result, 15 clinical trial sites are positioned to transition to commercial use of RenovoCath in H2 2026. This is a massive de-risked driver, as these sites already possess Vac approvals, trained physicians, and established procedural workflows.
Innovation: Expansion Beyond Pancreatic Cancer
Accelerating. For the first time, a physician utilized the FDA-cleared RenovoCath to deliver therapy to a patient with Sarcoma in a commercial setting. This physician-driven, off-label expansion beyond locally advanced pancreatic cancer (LAPC) validates the TAMP platform's versatility and drastically expands the Total Addressable Market (TAM) beyond the initial $400M LAPC estimate.
Contradictory Cash Runway Narrative
Reversing. Management explicitly claims $9.5M in cash is 'sufficient to fund operations into the second half of 2027' and targets a Q4 2027 breakeven. However, Q2 net loss was $2.9M. Even factoring in gross margins from accelerating revenue, burning ~$2.5M to $3.0M per quarter means $9.5M lasts roughly 3 to 4 quarters (mid-2027 at best), leaving zero buffer for the 6 quarters required to hit the breakeven target.
SG&A Expense Ramp Outpacing Revenue
Decelerating margin leverage. While revenue grew an impressive 115% YoY, SG&A expenses surged 91% YoY to $2.9M (from $1.5M in 25Q2). The company is spending heavily to build its commercial infrastructure. Until SG&A stabilizes, the impressive 84% gross margins will not translate into a meaningful reduction in cash burn.
The Long Wait for TIGeR-PaC Data
Stable. While commercial execution is taking the spotlight, the ultimate binary catalyst for the company—the Phase III TIGeR-PaC overall survival data—will not be available until the second half of 2027 (requiring 86 patient deaths, currently at 78). The company must survive purely on commercial device sales for another 12-18 months before unlocking the value of a drug-device combination approval.
Other KPIs
Stable. Gross margins remain exceptional and consistent (84.3% in Q2 vs 85.1% in Q1). This structural profitability confirms the highly accretive nature of the single-use RenovoCath device and proves that unit economics will support the business if volume scales.
Decelerating. R&D costs fell YoY from $1.4M to $1.2M as the heavy lifting of the Phase III TIGeR-PaC trial enrollment concluded. This line item should continue to taper, shifting capital allocation entirely toward commercialization efforts.
Guidance
Accelerating. The company raised and tightened its guidance from a prior range of $3.0M-$4.0M. The midpoint ($4.0M) implies massive 257% YoY growth compared to FY25 revenue of $1.1M. Achieving this requires H2 2026 revenue of ~$2.5M, implying continued aggressive QoQ step-ups.
Management stated that reaching a quarterly revenue run-rate of approximately $5 million positions the company at cash-flow break-even, and their internal plan anticipates hitting this by Q4 2027.
Key Questions
Bridging the Cash Gap
You are targeting cash flow breakeven by Q4 2027, but with $9.5M in cash and a Q2 net loss of $2.9M, you have roughly 3-4 quarters of runway. What specific levers will you pull to bridge the financing gap between mid-2027 and your Q4 2027 target?
H2 Guidance Dependency
Your raised guidance implies roughly $2.5M in H2 revenue. How much of this is derisked by the 15 TIGeR-PaC trial sites converting to commercial use, versus reliance on entirely net-new hospital Vac approvals?
Sarcoma Expansion Strategy
Following the first commercial use of RenovoCath in a Sarcoma patient, is your lean commercial team actively detailing the device for solid tumors outside of pancreatic cancer, or is this purely reactive, organic physician adoption?